These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24439735)

  • 21. The role of calcium and non calcium-based phosphate binders in chronic kidney disease.
    Elder GJ; Center J
    Nephrology (Carlton); 2017 Mar; 22 Suppl 2():42-46. PubMed ID: 28429551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperphosphatemia in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study.
    Bleyer AJ
    Am J Kidney Dis; 2008 Nov; 52(5):1024; author reply 1025. PubMed ID: 18971019
    [No Abstract]   [Full Text] [Related]  

  • 23. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphate Binders and Nonphosphate Effects in the Gastrointestinal Tract.
    Biruete A; Hill Gallant KM; Lindemann SR; Wiese GN; Chen NX; Moe SM
    J Ren Nutr; 2020 Jan; 30(1):4-10. PubMed ID: 30846238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Phosphate binders : What are the recent evidences ?].
    Bouajila IA; Martin PY; De Seigneux S
    Rev Med Suisse; 2017 Feb; 13(551):468-472. PubMed ID: 28714648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
    Ureña Torres PA
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?
    Malindretos P
    Expert Opin Pharmacother; 2012 Nov; 13(16):2255-6. PubMed ID: 23046412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphate binders. Is selection determined by price?: Yes.
    de Francisco AL
    Nefrologia; 2012; 32(2):235-9. PubMed ID: 22466264
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.
    West SL; Swan VJ; Jamal SA
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S41-7. PubMed ID: 20089502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
    J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis.
    Saif I; Halim A; Altaf A; Saif M; Khalid M; Ahmad D; Imran H
    J Ayub Med Coll Abbottabad; 2007; 19(4):26-8. PubMed ID: 18693591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
    Hanafusa N
    Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
    Locatelli F; Del Vecchio L
    J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
    Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ
    Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating hyperphosphatemia - current and advancing drugs.
    Ketteler M; Liangos O; Biggar PH
    Expert Opin Pharmacother; 2016 Oct; 17(14):1873-9. PubMed ID: 27643443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.